Company Details

GLOAS Limited

Lab Bench 10d-f, Unit 708-716, 7/F, 17W & Cubicle 10 (S72-73, S75-76), 6/F, Building 17W No. 17 Science Park West Avenue Hong Kong Science Park,Pak Shek Kok,N.T.
'+852 63008580
Dr. Thomas Leon

The information provided on this page is for reference only. Please refer to the latest information published by the partner company.

Our mission is to revolutionise drug and therapeutic discovery & development, and provide a novel and affordable solution for medical treatment, patient stratification and disease diagnostics for rare diseases of newborns.
We observed that there is a lack of effective treatment for rare diseases of newborns and there is an urgent need of human organ proxies in the dish for disease modelling, and biomarker, drug and therapeutic discovery.
To fill the gap, we will provide state-of-the-art and first-in-class human disease organoids for personalised precision medicine, regenerative medicine and preventive medicine for rare diseases of newborns. Our organoid platform marks the beginning of the deployment of a novel and affordable solution for medical treatment, patient stratification and disease diagnostics. Our platform will have a significant impact in reducing mortality rate, saving billions of dollars in healthcare costs and improving the quality of life of individuals.

Our human IPSC-derived organoids is an immediate solution to the problem.

An organoid is a miniaturised and simplified version of an organ produced in vitro in 3-dimensions that shows realistic micro-anatomy, resembling a near-to-native mini-organ in the dish. They are derived from tissue stem cells, embryonic stem cells or induced pluripotent stem cells (IPSCs), which can self-organise in 3-dimensional culture owing to their self-renewal and differentiation capacities. Organoids are used by scientists to study diseases and treatments in a laboratory.

GLOAS provides state-of-the-art technology platforms including patients’/normal human induced pluripotent stem cells (hIPSCs); first-generation patient’s/normal hIPSC-derived human organoids with one cell type (human organoids 1.0); second-generation advanced patient’s/normal human organoids with multiple cell types (human organoids 2.0); tissue hydrogel; and fabricated human bile duct to revolutionise the discovery and development of drugs and therapeutics for neonatal rare diseases.